Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

PHASE4RecruitingINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

August 14, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Epilepsy
Interventions
DRUG

Methylphenidate

10mg twice per day, at 8am and 12pm, for one week, then increased to 20mg twice daily, at 8am and 12pm, for the next 7 weeks during the double-blinded period.

OTHER

Placebo

When assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 8 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.

DRUG

Methylphenidate

During the open-label extension phase, dosing will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.

Trial Locations (4)

33125

RECRUITING

Miami VA Healthcare System, Miami, FL, Miami

02130-4817

RECRUITING

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston

10010-5011

RECRUITING

VA NY Harbor Healthcare System, New York, NY, New York

97207-2964

RECRUITING

VA Portland Health Care System, Portland, OR, Portland

All Listed Sponsors
collaborator

VA New York Harbor Healthcare System

FED

collaborator

Portland VA Medical Center

FED

collaborator

Miami VA Healthcare System

FED

collaborator

VA Boston Healthcare System

FED

lead

VA Office of Research and Development

FED